{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "10000877",
    "licUnit": "1",
    "validDate": "2029-03-11 00:00:00.000",
    "issueDate": "2009-03-11 00:00:00.000",
    "oriIssueDate": "2009-03-11",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA01000087701",
    "prodNameC": "爾必得舒 注射液 5 毫克\/毫升",
    "prodNameE": "Erbitux 5mg\/ml Solution for infusion",
    "indicationsName": [
        "適用於治療RAS原生型(wild-type)之轉移性直腸結腸癌病人\n• 與FOLFIRI (Folinic acid\/ 5-FU\/ Irinotecan)合併使用之第一線治療。\n• 與FOLFOX合併使用之第一線治療。\n併用encorafenib，⽤於治療帶有BRAF V600E 突變且曾接受過治療之轉移性直腸結腸癌 (CRC) 成人病人。\n與放射線療法合併使用，治療局部晚期之口咽癌、下咽癌及喉癌病人。\n與內含platinum類之化學療法合併使用，治療復發及\/或轉移性頭頸部鱗狀細胞癌病人。"
    ],
    "does": "2270",
    "packageUnit": [
        {
            "packageSpec": "20毫升",
            "packageUnit": "1A"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        },
        {
            "packageSpec": "100毫升",
            "packageUnit": "1A"
        }
    ],
    "medMCode": "05",
    "maMedCode": null,
    "medDCode": null,
    "mainCategory": null,
    "drBaseId": "0E20CBE2-24D8-428A-B375-C2856C4B93AD",
    "subCategory": [],
    "ingredientsDesc": [
        "CETUXIMAB, CHIMERIC ANTIBODY"
    ],
    "restraintItemsCode": [
        "02 輸 入"
    ],
    "applicantName": "台灣默克股份有限公司",
    "applicantAddr": "臺北市南港區經貿二路121號20樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": null,
    "mdKind": [],
    "monitorDate": null,
    "licidNew": null,
    "licidOld": null,
    "manuImportDesc": "廠商未登錄資料",
    "licManuImport": "2",
    "factoryDtoList": [
        {
            "id": "CAB075B6-E6E8-4A14-9017-B7AE68B2589E",
            "factoryCode": "1",
            "factoryName": "Merck Healthcare KGaA ",
            "factoryAddr": "FRANKFURTER STRASSE 250, 64293 DARMSTADT, GERMANY",
            "factoryCompanyAddr": "",
            "countryCode": "DE",
            "processCode": [
                {
                    "value": "3I",
                    "name": "自濃縮原料藥(Concentrated bulk)之稀釋(Dilution或Formulation)作業至成品製劑、一級及二級包裝作業。"
                }
            ],
            "processCodeStr": "3I;自濃縮原料藥(Concentrated bulk)之稀釋(Dilution或Formulation)作業至成品製劑、一級及二級包裝作業。",
            "factoryKind": "M",
            "factoryNo": "FDE0076500",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "BF5865DB-A7F2-4B46-919B-BD2EF5584451",
            "factoryCode": "2",
            "factoryName": "MERCK SERONO S.A.-CORSIER-SUR-VEVEY",
            "factoryAddr": "ROUTE DE FENIL, 25 ZONE INDUSTRIELLE B, 1804 CORSIER-SUR-VEVEY, SWITZERLAND",
            "factoryCompanyAddr": null,
            "countryCode": "CH",
            "processCode": [
                {
                    "value": "3H",
                    "name": "原料藥(Cetuximab)自工作細胞庫至濃縮原料藥(Concentrated bulk)之製造階段。"
                }
            ],
            "processCodeStr": "3H;原料藥(Cetuximab)自工作細胞庫至濃縮原料藥(Concentrated bulk)之製造階段。",
            "factoryKind": "M",
            "factoryNo": "FCH0283000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013000900",
            "ingredientsName": "CETUXIMAB, CHIMERIC ANTIBODY",
            "ingredientsDesc": "CETUXIMAB, CHIMERIC ANTIBODY",
            "concentDesc": null,
            "concent": "5.000000",
            "concentUnit": "001",
            "seq": "0",
            "prescription_seq": "0",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FE01"
        }
    ],
    "udiInfoList": [],
    "licBaseId": "54AA9AE8-1EEF-4366-9840-D9E1EABBE7EB"
}